规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | LNP023 hydrochloride is an orally bioavailable, highly potent, and highly selective inhibitor of factor B. LNP023 exhibits direct, reversible, and high-affinity binding to human factor B, with a KD of 7.9 nM. |
Animal study | LNP023 (20-180 mg/kg; oral administration) prevents KRN (150 μL)-induced arthritis in mice. It is efficacious when administered prophylactically or therapeutically in an experimental model of membranous nephropathy in rats [2].LNP023 demonstrates moderate half-lives (T1/2; Wistar Han rats: 3.4 h, beagle dogs: 5.5 h) and Cmax values (Wistar Han rats: 410 nM, beagle dogs: 2200 nM) after oral dosing (rats: 30 mg/kg, dogs: 10 mg/kg)[3].LNP023 shows terminal elimination half-lives (T1/2; Wistar Han rats: 7 h, beagle dogs: 5.6 h) resulting from high plasma clearance rates (8 mL/min/kg for rats and 2 mL/min/kg for dogs) and substantial volumes of distribution (2.3 L/kg for rats and 0.6 L/kg for dogs) after intravenous administration (rats: 1.0 mg/kg, dogs: 0.1 mg/kg)[3]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.18mL 0.44mL 0.22mL |
10.89mL 2.18mL 1.09mL |
21.79mL 4.36mL 2.18mL |
CAS号 | 1646321-63-2 |
分子式 | C25H31ClN2O4 |
分子量 | 458.98 |
SMILES Code | O=C(O)C1=CC=C([C@H]2N(CC3=C(OC)C=C(C)C4=C3C=CN4)CC[C@H](OCC)C2)C=C1.[H]Cl |
MDL No. | N/A |
别名 | LNP023 hydrochloride; Iptacopan Hydrochloride |
运输 | 蓝冰 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere, 2-8°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|